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Synthetic phosphoethanolamine and the transfiguration of 
immunopolitics in Brazil 
  Márcio Vilar 
Abstract  
The chemical substance synthetic phosphoethanolamine (fosfoetanolamina sintética) was 
developed at the University of São Paulo (USP) in Brazil at the beginning of the 1990s and, 
until 2014, was tested on and distributed to cancer patients by members of USP’s Chemistry 
Institute (IQSC) in the city of São Carlos. That year, the production and distribution of ‘Fosfo’, 
as it became popularly known, was forbidden by IQSC’s director with the support of USP’s 
rector and the Brazilian National Sanitary Surveillance Agency (ANVISA). Shortly after this 
first prohibition, however, Fosfo gained popularity and became a national symbol of local 
scientific innovation and hope for a cancer cure. Likewise, it became an object of regulatory 
disputes involving multiple sectors of Brazilian society. Despite several further efforts by some 
scientists and patients to legitimate Fosfo as a pharmaceutical, ANVISA never authorized it. 
Nevertheless, at the same time as parts of Brazil’s established medical communities were 
becoming suspicious of Fosfo, its informal production and dissemination were increasing 
surreptitiously, with many Fosfo users and stakeholders questioning the legitimacy of 
conventional cancer therapies. In this article, I aim to understand the impact of Fosfo as a 
biotechnological innovation in terms of the ‘transfiguration’ of the physical and juridical 
persons involved in this controversy. Through the lens of transfiguration, the engagement and 
therapeutic-regulatory experiences of Fosfo users and stakeholders appear as deviant journeys 
that introduce discontinuities into established biomedicine and imply radical transformations 
at multiple levels, ranging from individuals to larger institutional environments. 
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Nobody joins the voice of a sheep with the shape of a horse, nor the colour of lead 
with the weight and fixedness of gold, to be the complex ideas of any real substances; 
unless he has a mind to fill his head with chimeras, and his discourse with unintelligible 
words. (Locke [1693] 1995, 369) 
 
And yet there are others, who, ‘losing their way, prefer to remain lost for ever’. This 
end of unreason, elsewhere, is transfiguration. (Foucault [1961] 2006, 530) 
Introduction 
Developed at the University of São Paulo (USP) in Brazil at the beginning of the 1990s, 
synthetic phosphoethanolamine (fosfoetanolamina sintética) was tested on and distributed to 
cancer patients by members of USP’s Chemistry Institute (IQSC) in the city of São Carlos.1 In 
2014, the production and distribution of ‘Fosfo’, as it became popularly known, was forbidden 
by the IQSC’s director with the support of USP’s rector and the Brazilian Health Regulatory 
Agency (ANVISA). Shortly after this first prohibition, however, Fosfo gained popularity and 
became a national symbol of local scientific innovation and hope for a cancer cure. Likewise, 
it became an object of regulatory disputes involving multiple sectors of Brazilian society. 
Despite several further efforts by scientists and patients to legitimate Fosfo as a 
pharmaceutical, ANVISA never authorized it. Nevertheless, whilst parts of Brazil’s established 
medical communities were becoming suspicious of Fosfo, its informal production and 
dissemination increased surreptitiously, driving many Fosfo users and stakeholders in turn to 
question the legitimacy of conventional cancer therapies. In this context, how do scientists, 
patients, and their respective relatives and friends mobilize to promote Fosfo in public spaces 
(including the internet) and in private spheres as a legitimate medical future? How, and to what 
effects, do they rethink and deal with regulatory agents and the biomedical establishment in 
Brazil and their use of global immunosuppression-based therapies? Not least, what role does 
Fosfo play in these struggles for therapeutic legitimacy? 
Unequal access to healthcare in Brazil remains highly prevalent, a symptom of deep historical 
socioeconomic inequalities. For this reason, especially since 2003, the Brazilian government 
 
1  All translations from Portuguese and German to English in this article were made 
by the author. 
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has reformulated and increasingly invested in Brazil’s publicly funded Unique Healthcare 
System (SUS). This has led to substantial growth in the poor classes’ ability to access healthcare 
(Landmann-Szwarcwald and Macinko 2016). According to Vera Coelho (2018), around 65 
percent of the Brazilian population access healthcare through SUS. In addition, as João Biehl 
(2016) argues, several Brazilian middle and low-income patients have brought lawsuits to 
justice courts in an attempt to get access to medications, in a twin phenomenon that implies 
the judicialization of healthcare and the pharmaceuticalization of socioeconomic rights. 
However, after the fall of the Worker’s Party government in 2016, a radical neoliberal politics 
of dismantling SUS was launched (Soares 2018). The Fosfo controversy rose and, apparently, 
disappeared within this period, having affected access and regulation of scientific innovation 
significantly. Yet, although now silent, the controversy continues at this very moment. 
My aim is to anthropologically understand the impact of Fosfo as a biotechnological 
innovation in terms of the transfiguration of physical and juridical persons involved in this 
controversy. I understand ‘transfiguration’ as the re-foundational unfolding of a person, by 
which their internal constituents are rearranged so as to systematically affect both the person 
themselves and their surrounding world. This unfolding takes place as the result of 
experiencing a transgressive encounter between oneself and a utopic, wished-for other that 
can trigger a process of decolonizing reordering across several scales (Venn 2000, 50). From 
the perspective of the transgressed order, transfiguration appears as deviance. Consequently, 
in the context of the Fosfo controversy, the engagement and therapeutic-regulatory 
experiences of Fosfo users and stakeholders appear through the analytical lens of 
transfiguration, as I use it here, to be deviant journeys. These deviant journeys introduce 
discontinuities into established biomedicine and imply radical connected transformations at 
multiple levels, ranging from body cells to larger institutional environments. Despite their 
transgressive character, I argue, these changes might paradoxically help to paradigmatically 
renew biomedicine rather than undermine it. 
In Brazil, people who have encountered the compound report experiences that have realigned 
and reorganized their bodies, minds, and worlds. This realignment has rendered them opposed 
to – and, yet, still networked with – disciplined physicians and cancer patients. Despite being 
developed by biomedical scientists, Fosfo emerges as a subversion and a rupture with 
established biomedicine instead of a logical consequence and extension of it. Yet, for the 
physicians and patients who use it, Fosfo is a biomedical entity that participates in the making 
of ‘Fosfo worlds’ and, as such, in the making of the contemporary life sciences. From an 
anthropological perspective, I am concerned with presenting and analyzing Fosfo worlds as 
informal circuits of pharmaceutical innovation, based on the experiencing of Fosfo as a 
biopolitical artefact. For this, I focus on the practices, moralities, and conceptualizations of 
people who have been affected by Fosfo and who, organizing themselves around it, are now 
Following ‘Fosfo’ 
 
 
 
 
90 
committed to its legitimization as an immunostimulant therapy for the treatment of cancer in 
contemporary Brazil. In so doing, I seek to situate the controversies about the use and 
regulation of Fosfo and other immunostimulants in Brazil mainly from the perspective of 
immunostimulants-users, as well as within broader debates regarding what counts as proof in 
science and medicine and for whom. 
Theoretical-methodological background 
As a case study, I situate the Fosfo controversy within my broader research on how scientific 
innovation, established biomedicine, and informal healthcare co-exist and interface in 
contemporary Brazil, and how their relations are mediated by legal and other institutions. 
Within this research, I delineate ‘life assemblages’ (Sleeboom-Faulkner 2014) as collectivities 
comprising, among others, medical doctors and patients who refuse the use of conventional 
drugs based on immunosuppression to treat autoimmune diseases (such as lupus, arthritis, 
multiple sclerosis, and cancer), and who instead embrace therapies based on the opposite 
principle of immunostimulation. Examples of the latter include autohemotherapy, vitamin D3, 
stem cell therapies, and animal poison-based treatments (Vilar 2018a). 
In my interpretation, life assemblages comprise flexible sets of associations and bionetworks 
that materialize a political economy of hope (Novas 2006). Their members ‘share questions 
related to the definition of what is “a life worth living” [and] mindsets that assume moral 
change towards life as inevitable and experience the transgression of ethical boundaries as a 
normal result of developments in science and technology’ (Sleeboom-Faulkner 2014, 2). While 
patients’ families and friends may form part of these networks, networks can also include 
people who do not know each other personally. People who use or support Fosfo, in this 
sense, co-constitute themselves and are co-constituted as members of Fosfo assemblages, or 
‘Fosfo users’ as I call them, through their personal immunological therapeutic experiences 
with Fosfo and their associations with related practices, knowledge, persons, and networks. 
There seem to be at least three factors that entwine members of Fosfo assemblages as 
biological citizens (Rose and Novas 2005) and allow Fosfo worlds to arise: first, the effect 
Fosfo has on them; second, their commitment to promoting Fosfo and other 
immunostimulant therapies to treat autoimmunity as legitimate scientific innovations; and 
third, the recurrent contestations of authorized therapies. All in all, the processes through 
which Fosfo assemblages come into being are informed by modes of experiencing 
autoimmunity, scientific innovation, and the biomedical establishment in Brazil, as well as 
exclusion and the liminality which results from rejecting conventional treatments and crossing 
legal boundaries. As I understand it, it is through a particular way of constituting themselves 
as persons in relation to and with others that Fosfo users actualize an immunological sociality 
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as relational matrix (Ingold 2001; Long and Moore 2013). This, in turn, enables them to know 
and sociobiologically reproduce themselves and their Fosfo worlds in a distinct way (i.e., as 
dissidents who promote a cure for cancer as a realizable utopia after having experienced 
contact with unauthorized knowledge, practices, and feelings linked to Fosfo as a tabooed 
drug).  
To analyze this experience in terms of transfiguration, I combine two notions of person: the 
person as fractal and the person as multiple. In line with this conceptual combination, just as 
one body is made from several interconnected bodies, their relationships to each other, and 
respective environments, I am assuming that every person is likewise multiply constituted 
(Schwartz 1987; Lorimer 2017, 32–36) and, by the same token, reproduces themselves in 
multiple forms as ‘different projections of its fractality’ (Wagner 1991, 163). In this sense, as 
actors, persons are also networks. Sociality, in turn, instigates the interconnectedness of 
potential actors who share certain longings, fears, moralities, and ethical imaginations, and 
points to ways in which these actors, who are also networks, relate with and enact parts of 
their constitutive multiplicities. Likewise, sociality – as a constantly actualized outcome of the 
experience of being-and-growing-in-the-world, to which becoming ill and healthy and 
encountering biomedical innovation belong – does not determine but, rather, pedagogically 
informs the organizing principles of life assemblages for Fosfo.  
A central point that I explore here is whether and how the emergence and dynamics of Fosfo 
worlds, as one among further life assemblages which support immunostimulant therapies for 
autoimmunity in Brazil, provoke and, in turn, are reinforced by a transfiguration of established 
biomedicine. My hypothesis is that life assemblages arise along the contradictions of 
established biomedicine itself and that, in the case of Fosfo and other immunostimulant 
therapies, the bionetworking practices of their members as biomedical dissidents converge to 
transfigure established biomedicine based on immunosuppressant pharmaceuticals. By 
following Fosfo and the people and institutions it has affected, I learn about the making of 
contemporary medico-legal orders as they responsively unfold through the transfiguration of 
related persons. These persons are involved in the disputes over legitimacy between conflicting 
immunological therapeutic models that contrary immunological socialities validate. 
Inspired by actor-network theory (Latour 1987), I sought to apprehend the Fosfo controversy 
as science in the making. Methodologically, I identified and traced key moments in the 
trajectory of Fosfo, drawing on a broad set of materials including media coverage, scientific 
articles, internet reports, websites and blogs, as well as official political, medical, and legal 
documents. These materials were collected on the internet using digital methods (Rogers 2013) 
as a way to combine online research and actor-network theory. First, to reconstitute the Fosfo 
controversy, I organized these materials into chronological order. Second, I identified multiple 
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actors engaged in co-administering cancer treatment, including scientists, laboratories, and 
health professionals, but also patients, their relatives and friends, judiciary officers, politicians, 
diverse associations, and private, State and Federal institutions. Third, I adapted grounded 
theory to set limits in my search; that is, when the statements and practices of Fosfo co-
regulators became repetitive and assumed a more crystallized form, I formulated them as 
theoretical constructs, changed my direction, and kept moving.  
Analytically, I consider the internet both as an archive (where one can find what exists outside 
it and what migrated to it) and as a set of mappable-mapping webs (through which one co-
produces realities but which also frame how users participate in this co-production of realities). 
I take the multiple practices of this myriad of actors towards Fosfo as co-constituting Fosfo 
itself in its many aspects – as a biotechnology, an object of legal dispute, a symbol of disillusion 
or of hope, etc. Hence, exchanges on the internet (e.g., on Facebook and personal blogs) 
between established authorities and a wide range of Fosfo stakeholders are central to my 
analysis. Because I am mainly concerned with the advent of Fosfo worlds, I focused on those 
exchanges that comprise unauthorized knowledge, legal documents and guidance about how 
to deal with law and legal authorities, therapeutic reports and recipes of how to self-produce 
Fosfo at home, personal experiences, and educational practices among people engaged in 
promoting the compound. By following and describing the bionetworking activities of Fosfo 
users and the trajectory of Fosfo, I seek to reassemble the biomedical world that members of 
immunostimulants-assemblages recreate. When taken as a set of effects related to 
biotechnological innovation as deviant journeys, this trajectory – including the re-
appropriations and multiple transformations that Fosfo both undergoes and provokes – 
implies what I call transfiguration. 
Finally, as a non-health professional, my analysis and personal position in relation to Fosfo are 
informed by participant observation conducted in the context of my research on other 
immunostimulant therapies, which includes autoethnography and membership in related 
networks. I elaborate and discuss my research and methods elsewhere (Vilar 2018a, 2018b). 
Because of my experience with immunostimulants – I recovered from psoriasis arthritis by 
using a stigmatized immunostimulant therapy – and due to a probable ongoing paradigm shift 
in the life sciences (CRC/IMPATH n.d.; Silva et al. 2015; Lorimer 2017; Vilar 2018a), I see 
the administration of immunostimulant therapies for autoimmunity conditions as, in principle, 
promising. Overall, while the Fosfo controversy contributes to current debates about the role 
of patients in the adoption of new biotechnologies into healthcare systems, an analytical 
perspective that focuses on transfiguration also helps to consider the position of biomedicine, 
along with non-biomedical actors, as an essential part of the renewal of and resistance to 
biomedicine itself. 
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Structure of the article 
This article is divided into two main parts. In the first part, I follow Fosfo from the moment 
it began to gain national prominence through mass media and on the internet in Brazil. I move 
with Fosfo from the laboratory to the bodies of cancer patients, and from there to private 
homes, the police, and justice courts, medical, regulatory and political institutions, and the 
informal sector. In the second part, I seek to turn transfiguration into a manageable 
anthropological tool, since its place within medical anthropology and science and technology 
studies is still not clear. To analyze Fosfo’s controversy through the lens of transfiguration, I 
experimentally transpose this concept from the context of transformation processes in 
religion, philosophy, and art to transformations in medical therapy involving biotechnological 
innovations. I conclude that, if sociality as a relational matrix informs the responsive coming 
together of actors into Fosfo assemblages on the basis of their shared experiences with 
conventional and unauthorized therapies, transfiguration may be used to denote the multiple 
changes in how these assemblages are composed; that is, the transformation and repositioning 
(or transformation through repositioning) of involved actors and their respective practices, 
minds, bodies, and worlds that take place through contact with unauthorized desired 
innovation as unpredictable other. 
The Fosfo controversy: Bringing science home, or give me a kitchen 
and I will manufacture the cancer cure 
In August 2015, journalist Stefhanie Piovesan (2015a) published an online article that sparked 
a long and heated public controversy concerning Fosfo. The article told the story of Mrs. 
Witthoeft, an eighty-two-year-old woman living in Santa Catarina State who, in March 2007, 
was diagnosed with cancer. Two months after the diagnosis, her son Carlos was told that there 
were scientists at USP who distributed a medication against the disease. He decided to 
investigate this and contacted the chemist and research coordinator Professor Gilberto 
Chierice, who provided him with pills that went by the name ‘Fosfo’. Eighteen days after his 
mother had taken the treatment, Carlos considered her ‘cured’. Mrs. Witthoeft was well known 
in her village, and as her neighbors and friends registered her recovery, they asked Carlos 
whether he could provide them with the same pills too. Although Carlos tried, Professor 
Chierice explained to him that the laboratory at USP did not have the capacity to produce 
enough pills for everybody. Carlos then asked him whether it was possible to learn how to 
produce Fosfo himself and kept insisting on the matter until Professor Chierice invited him 
to São Carlos. 
During his short stays over the following four months, Carlos received intensive training in 
basic chemistry and learned how to synthetize Fosfo. Subsequently, he began to produce Fosfo 
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pills at home and distribute them for free with his wife Rita, who was responsible for receiving 
calls and comforting patients. This Fosfo assemblage flourished further. For half a year, Carlos 
continued to produce and distribute Fosfo while working as a re-seller. As he told it, demand 
kept increasing: ‘Each person who was cured would bring three or four more people’ (quoted 
in Piovesan 2015a). Many people began to help and, at some point, Carlos and Rita began to 
dedicate themselves exclusively to the production and distribution of the pills. In parallel, over 
the ensuing years, Professor Chierice and his team published at least ten articles in 
internationally renowned scientific journals in Europe and the USA reporting on their 
experiments with Fosfo. 
The interdiction of Fosfo and its image in mass media 
On 10 June 2014, the IQSC’s director stated that the production and distribution of Fosfo 
and any other drug at the IQSC could only be realized after registration with ANVISA and 
subsequent approval by the IQSC’s board of directors (USP/IQSC 2014). As Fosfo was not 
registered, Professor Chierice and his team had to stop its production and distribution 
immediately. Due to this interdiction, many patients, including those who were undergoing 
treatment with Fosfo and others who wished to start taking it, began to judicialize their access 
to Fosfo by going to the local public defender’s office to apply for injunctions. Eventually, 
through these lawsuits, they received permission from the justice courts to resume or 
commence their treatment with Fosfo (Piovesan 2015b; Marcio 2015). 
One year later, the police appeared at Carlos’s door and ANVISA confiscated all his materials. 
His production of Fosfo was stopped and he was accused of ‘pharmaceutical falsification’, 
ultimately spending seventeen days in jail. ANVISA justified its actions by stating that Fosfo 
was not officially registered. In the reportage on this incident published immediately after his 
imprisonment (G1 2015a), Carlos’s name was not mentioned; instead, he was portrayed as ‘a 
man’ suspected of cheating people with his self-produced drugs. This news story was almost 
entirely based on an interview given by the director of the regional ANVISA office. According 
to her, ‘the producer’ prescribed his patients with three pills to be taken daily and promised 
recovery within six months (ibid.). Furthermore: 
the same patient should not consume chemical medicines which were scientifically 
attested. He also used to forbid radiotherapy [and] chemotherapy, given that these 
treatments would significantly reduce the effects of his medicine, and he also used to 
forbid the use of antibiotics. (ibid.) 
Nevertheless, one month after that reportage, ANVISA’s portrait of Carlos was radically re-
shaped through subsequent news that showed him as a Prometheus-like character, struggling 
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to give people with cancer access to a drug that, despite all controversies, represented a hope 
for a cure. When Carlos was released from jail, his wife Rita unexpectedly died of an aneurism. 
This case was published in newspapers, on the internet, and on television, provoking great 
commotion. 
Coverage of this story made not only the ‘cancer pill’ public, but also the struggles among 
scientific authorities and between non-scientists, ANVISA, and further legal agents (G1 
2015a). An unanswered question arising from the debates concerning Fosfo, which helps to 
put the legitimacy of regulatory science in Brazil into question, is: why was Fosfo forbidden at 
that time, even though it has been distributed for over twenty years with the consent of the 
authorities? It was at this time that, having previously remained unnoted, the narratives of 
people who had posted their therapeutic stories of being cured by Fosfo on different internet 
blogs, discussion forums, and in personal videos on YouTube began to be taken seriously, 
amplified, and reproduced. At the same time, it also became clear that many people had 
achieved access to Fosfo through lawsuits at justice courts following the prohibition on Fosfo 
production at USP. With the publicization of Fosfo, the number of such injunctions multiplied 
(Piovezan 2015b). 
Engaging the immune system 
To understand the adoption of Fosfo by Fosfo users and their disapproval of conventional 
therapies such as chemotherapy, radiotherapy, and antibiotics, it is necessary to understand 
the ways in which conventional therapy and Fosfo mutually exclude each other as 
incommensurable therapeutic models. Cancer is usually not referred to as an autoimmune 
disease within biomedicine. Nevertheless, it is, in principle, a disease provoked by regulation 
problems of the immune system rather than by organic pathogens such as a virus or bacterium. 
According to the US National Cancer Institute: 
Cancer can start almost anywhere in the human body, which is made up of trillions of 
cells. Normally, human cells grow and divide to form new cells as the body needs them. 
When cells grow old or become damaged, they die, and new cells take their place. When 
cancer develops, however, this orderly process breaks down. As cells become more and 
more abnormal, old or damaged cells survive when they should die, and new cells form 
when they are not needed. These extra cells can divide without stopping and may form 
growths called tumors. (NIH NCI 2015) 
The uncontrolled, incessant reproduction of dysfunctional cells which characterizes cancer 
occurs because the immune system fails to distinguish them as damaging anomalies from 
healthy cells. Unlike diseases such as arthritis and lupus, which are identified through 
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exacerbated autoimmune reactions against healthy cells, cancer presents an absence of 
immunological reaction, or neglect, towards unhealthy cells. In both cases, however, the 
immune system acts inappropriately. Correspondingly, people with cancer and other 
autoimmune diseases are conventionally treated by physicians with immunosuppressants to 
palliatively turn off the patient’s immune response. That is achieved by artificially damaging the 
patient’s metabolism to slow down cell production, thereby slowing down the disease’s 
progress so as to avoid further damage.  
In contrast, Fosfo stimulates immunity and the production of antibodies in those who take it. 
As one of the Fosfo scientists, Renato Meneguelo (quoted in NSC Total 2015), summarizes: 
Once in the body, the substance [Fosfo] hits the mitochondria and signals the cancer 
cells. Through the body’s own defense, the marked cells go through the process of 
apoptosis (‘programmed death cell’), decreasing its multiplication and thus preventing 
the cancer from evolving or going to other tissues. 
Metaphorically speaking, Fosfo can be thought of as a pair of ‘spectacles’ that help the immune 
system to once again ‘see’ abnormal cells and so respond accordingly, in that it stimulates a 
sort of immunological awareness. Thus, instead of being considered as the problem and 
something that needs to be punished, the cancer patient’s immunity is re-validated, enhanced, 
and re-committed through didactic stimulation; it is taken as the main part of the solution 
(Napier 2012). As with other immunostimulants, Fosfo can be grouped into the category of 
regenerative medicines, as a biotechnology ‘involved in the collective project meant to coax 
the body to repair itself and potentially to extend the lifespan’ (Hogle 2007, 859). Hence, Fosfo 
users do not recommend immunosuppressive therapies. 
The apparent incommensurability – and, therefore, the disputes for therapeutic legitimacy – 
between Fosfo (as a biomedical innovation based on immunostimulation) and conventional 
therapies (based on immunosuppression) became manifest through different encounters that 
take place at clinic offices, justice courts and governmental institutions. Here, I would like to 
return to the judicialization of Fosfo as an act of co-regulation of immunity and cancer 
treatment. 
Judicial actors and regulatory science 
Because Fosfo was not registered at ANVISA as required, the injunctions to obtain Fosfo 
were mainly based on three legal assumptions. First, the Brazilian Federal Constitution of 1988 
assures the ‘right of patients to health’ as universal. Second, law n. 6.360 (art. 24) states that 
new medicines, exclusively for experimental use and under medical control, are exempt from 
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registration. And third, it takes the ‘Extraordinary Appeal Nr. 657.718 MG’ (STF 2011) as a 
legal precedent (in this case, a patient with chronic kidney disease successfully requested the 
Brazilian Federal Government for access to a medication that had been prescribed by a 
physician but, at that time, could only be found outside Brazil and consequently was not 
officially registered with Brazilian regulatory institutions). Additional arguments were made 
that patients with cancer had no time because ‘cancer does not wait’, that conventional 
treatments have not been successful, and that terminal patients have nothing more to lose 
after they had passed through conventional therapy. 
As reports of people managing to get access to Fosfo through the judiciary continued to 
emerge, people from across the country went to the Public Defender’s Office in the city of 
São Carlos or began to employ local lawyers to obtain Fosfo (STF 2015a). Successful models 
of legal claims, provided by lawyers of the Public Defender’s Office and by successful 
claimants, began to circulate on the internet, where interested people could download and 
adapt them. Favorable sentences were also publicly exchanged, to serve as templates for judges 
who were in favor of Fosfo (e.g., Rocha 2016; da Silva 2015; Tarabori 2015). On social media, 
the number of narratives reporting a cure through Fosfo increased.  
In September 2015, the president of the São Paulo State Court contested more than 360 
injunctions, which had been granted by the justice court in São Carlos (G1 2015b). Beyond 
the fact that ‘the referred substance is not among the commercialized drugs’ and ‘it is not 
registered by ANVISA’, he defended that ‘it could not even be argued that health protection 
prevails over the formal registration of the drug, because there is no evidence that the required 
substance, which is not a remedy, has any effect in humans’ (TJ-SP 2017, 6–7). One person 
whose injunction was blocked was the mother of a lawyer, who subsequently brought her case 
to the Brazilian Supreme Federal Court (STF) in Brasília, the highest judicial court in the 
country. The petition was judged in their favor (Knoploch, Brigido, and Souto 2015). This 
decision set another legal precedent on the federal level, leading to more injunctions being 
granted by justice courts outside São Paulo State across the country (STF 2015b). After that, 
the president of São Paulo State Court withdrew his prohibition of Fosfo. 
Fosfo at the Brazilian Senate 
As required by senators, a public hearing with live transmission took place on 29 October 
2015 at the Brazilian Senate to debate the ‘discovery and development of pharmaco-medical-
clinic research with the drug phosphoethanolamine’ (Senado Federal 2015; TV Senado 2015). 
During the hearing, the main actors involved in the controversy expressed their respective 
positions. A statement from USP’s rectory was read out, which emphasized that USP was 
inappropriately obligated to provide Fosfo for those who require it by force of law (TV Senado 
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2015, from 31:20). It argued that Fosfo was not a pharmaceutical, but a chemical product 
without clinical evidence for its therapeutic efficacy. Furthermore, it was neither registered nor 
authorized by ANVISA, and ‘the manufacture of this substance, being handmade, does not 
fulfil the international and national requirements for the medicament production’ (ibid.). The 
statement concluded with a warning that the USP was investigating ‘the possibility of 
informing on the professionals who are benefiting from the despair and fragility of the families 
and the patients to the prosecution authorities’ (ibid.). After the reading, the senator suggested 
that the USP’s note may frame the debate which should follow.  
Despite this menacing tone, the following presentations from Fosfo users took place 
unintimidated. According to Professor Chierice (TV Senado 2015, from 37:20), in 1995 USP 
had made an agreement with a hospital, through which it became a research hospital and 
received support from the Ministry of Health. Because ANVISA did not exist at that time, 
research on Fosfo was initiated ‘per the rules of the Ministry of Health’ (ibid.). With this, all 
necessary authorizations had been achieved and tests were conducted with ministerial 
authorization. However, the agreement was not renewed by the hospital in the year 2000, 
meaning that patients who were taking the pills could no longer receive them at the hospital 
and had to seek them at USP’s laboratory in São Carlos. The number of patients seeking Fosfo 
at USP increased ‘in an uncontrolled manner, but we [as chemists and university researchers] 
never entered into the medical field, because all the recommendations came from the hospital’ 
(ibid.). Stating that there were several cases of cured people over twenty years, Professor 
Salvador Claro Neto, a key member of the team responsible for synthesizing Fosfo at USP 
summarized their moral dilemma: ‘How can a person in full recovery process, suddenly, have 
no further access to Fosfo? That is not even human! […] Fosfo is, nowadays, a reality for the 
cancer cure’ (ibid., from 52:50). Later in the hearing, additional members of the USP research 
team explained how Fosfo works, why it has no side effects, and why it is affordable. They 
further discussed the experiments they had conducted (partially enabled through cooperation 
with other renowned institutions such as the Butantan Institute and São Paulo State 
University) and their published results. They emphasized that their work was financially 
supported by national research agencies and showed images of experiments with Fosfo in 
animals and humans. Among them, one stated that he had been taking the substance himself. 
Another, Professor Marcos de Almeida, appealed for a conciliation, which was noteworthy in 
that it did not exclude established therapies, arguing for the approval of Fosfo for patients in 
terminal stage. He further noted that the statements of patients who had used Fosfo should 
be seriously considered ‘even without the due clinical control for its liberalization’ (TV Senado 
2015, from 1:01:00). Almeida’s main argument was based on the number of people who had 
accessed Fosfo through injunctions and whose health has subsequently improved. Speaking 
as a member of Professor Chierice’s team, he stated that they would give up the patent rights 
of Fosfo provided that it begins to be distributed through SUS and at a low cost. After 
Professor Chierice’s team, ANVISA’s president explained ANVISA’s role in a didactic fashion 
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and stated that evaluating a formal application for Fosfo’s approval was a matter of high 
priority, affirming that ANVISA would help scientists to organize the missing clinical tests 
(TV Senado 2015, from 2:31:00). He emphasized, however, that nobody had entered with a 
request to approve Fosfo until that moment. 
In their turn to speak, Fosfo users underpinned the Fosfo scientists’ statements. One user, 
Ms. Cioffi, presented herself as a ‘carrier of metastatic breast cancer with bone metastases’ 
(TV Senado 2015, from 3:06:30). As she stated, no conventional therapies had shown any 
efficacy during her palliative treatment, but with Fosfo, everything had changed: 
When I looked for the phosphoethanolamine, I had, as all patients have, numerous 
doubts. It is not easy for a patient to obtain a medication through an injunction, 
through a lawsuit, to receive in their house a transparent envelope without a label, 
without an expiration date, without terms, without a manufacturing batch, without 
prescription, with nothing, having to believe […] that there is a chance. I have been 
using phosphoethanolamine since 23 September. […] If it is effective, I do not know. 
I only know that my tumor markers, for the first time […] have gone down. […] It is 
also true that since the fourth day of use I no longer use any analgesic. And the cancer 
patient knows what I’m talking about (ibid.). 
After having reported on further radical health improvement through Fosfo, Ms. Cioffi asked 
to continue using it, at least to avoid having to return to the use of analgesics and morphine. 
Likewise, Mr. Vilson reported that since taking Fosfo, he no longer needed to undergo 
chemotherapy, which he was very afraid of (TV Senado 2015, from 3:16:00). Moreover, he 
presented himself as evidence for Fosfo’s efficacy. He explained that he had built a network 
around Fosfo, stating ‘I am helping as many people as possible [with Fosfo]’ and asking ‘Does 
one have to enter the judiciary to become healthy?’ (ibid.). He then warned: ‘The ANVISA’s 
president may have, tomorrow, a relative diagnosed with cancer just as it may happen to each 
one of you [in the audience]. Therefore, let’s solve this problem’ (ibid.). Towards the end of 
the hearing, a federal public defender also presented a lawsuit initiated by the Federal Public 
Defender’s Office (TV Senado 2015, from 5:00:30). It aimed to ensure the continuity of 
Fosfo’s production and distribution on the national level within sixty days. The defendants in 
this lawsuit were the Federal Government of Brazil, ANVISA, São Paulo State, and USP, all 
of whom were given seventy-two hours to respond.  
As an outcome of the hearing, the government committed itself to fully support Fosfo 
scientists and financially enable the final clinical tests. Several commissions bridging different 
ministries were assigned the responsibility of forming a work group with a network of 
hospitals, clinics, and universities. Furthermore, through a Bill, Fosfo’s production would be 
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resumed to meet the injunctions and be given to patients in terminal stages who would take 
the drug at their own risk. 
Immunopolitics in trance 
In February 2016, São Paulo’s governor designated the PDT Pharma laboratory as an 
authorized place for the production of Fosfo, under the supervision of Professor Chierice and 
Professor Claro Neto. Planned clinical tests were to be coordinated by the São Paulo Institute 
of Cancer with authorization from the National Research Ethics Commission. After being 
synthetized at PDT Pharma, Fosfo would be encapsulated at the official São Paulo State 
laboratory. On 8 March, the Chamber of Deputies approved a Bill for the liberalization of 
Fosfo. One week later, the Federal Pharmacy Council (CFF) published a ‘technical note’ 
advising that ‘the use of this substance, empirically and without sufficient scientific support 
for safety and efficacy, exposes its users to possible damage and creates false expectations of 
cure that may not be confirmed’ (CFF 2016). On 17 March, partial results of pre-clinical tests 
were published claiming that Fosfo contained much less phosphoethanolamine than expected 
and was of low efficacy, although it did not appear to be toxic. 
After Fosfo users and stakeholders officially contested the proceedings of the ongoing pre-
clinical tests, new meetings were scheduled. On 22 March, the Senate approved the Fosfo Bill 
sent by the Chamber of Deputies. However, one week later, USP denounced Professor 
Chierice for ‘healerism’ (curandeirismo), and he was required to attend an interrogation by the 
police (G1 2016a; Boehm 2016) while USP’s rectory publicly reaffirmed its position and closed 
the IQSC’s laboratory (USP 2016). On 5 April, at the Federal Senate, the debate on the partial 
results of the pre-clinical tests was resumed (TV Senado 2016). Afterwards, a prosecutor who 
accompanied the debate stated during an interview that: 
A wrong methodology [to scientifically evaluate Fosfo efficacy] was used […]. They 
[the scientists who were conducting the tests] have stated that Fosfo has low 
therapeutic purpose. This is not true. We have documents in the opposite direction 
and, unfortunately, this issue, which should be resolved by science, will have to be 
resolved in the judiciary. (G1 2016b, from 1:49) 
Eight days later, the Presidency approved the PLC 3/2016, turning it into Law 13.269, 
liberalizing Fosfo. At this point, the impact of Fosfo on ordinary dying cancer patients and 
the people who support them seemed to have repositioned the very sources of legitimate 
knowledge and authority. In April 2016, the liberalization of Fosfo was sanctioned by the 
Brazilian president (Presidência da República 2016). Although this law was programmed to 
lose its validity when all necessary clinical tests were concluded, it implied that the official 
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criteria of established biomedicine to verify and affirm the truth about any substance could be 
(and, indeed, were) transfiguratively subsumed into the set of evaluation criteria used by Fosfo 
assemblages’ members. Between the public hearing at the Senate and its legalization, Fosfo 
continued to move along different scrutinizing paths of innovation and contestation in world-
making entanglements between different parts of Brazil’s economic, judicial, pharmaceutical, 
political, and media systems. 
In this sense, the combined impacts of new media technologies, economic and health 
demands, legal dispositions, and innovative biotechnologies appear as a succession of 
transfiguration processes, since the changes in the scope of what is to be trusted and 
envisioned, and of valid risks, belong to the main effects that characterize transfiguration. As 
part of these processes, Fosfo assemblages’ members, as those who co-produce contesting 
medical evidence in favor of Fosfo, unfold themselves as persons capable of systematic 
evaluation and, hence, as reliable witnesses of the healing powers of Fosfo as an innovative 
substance. At the same time, the claims of established biomedicine are eclipsed by suspicions 
of scientific misconduct. 
Again, however, the tide turned. Three days after Fosfo was legalized, the Brazilian Medical 
Association entered a judicial action against it at the STF, arguing that Law 13.269 was 
unconstitutional. On 17 May, a seminar to discuss preliminary studies on Fosfo took place, 
this time without the presence of Fosfo users and stakeholders (INCA 2016). On 19 May, one 
week after the Brazilian President was deposed through a parliamentary coup (Jinkings, Doria 
and Cleto 2016), the STF suspended the Fosfo law (STF n.d.). Furthermore, in March 2017, 
the clinical tests were interrupted. According to Natália Caetano et al. (2017, 111), because 
most of the tests with Fosfo ‘did not show any clinical efficacy in preliminary trials and clinical 
trials supported by São Paulo Cancer Institute, studies were suspended with the agreement of 
[…] ANVISA’. Yet, the conduct of these clinical tests was also contested, and in October a 
Parliamentary Committee of Inquiry (CPI) was formed at the São Paulo Legislative Assembly 
to investigate why São Paulo State was not supporting clinical studies for the liberalization of 
Fosfo. 
Despite its legal suspension, Fosfo reappeared as an authorized drug for the treatment of 
cancer in January 2018. In April of that year, the members of the CPI recommended in their 
final approved report, among other proceedings, that new tests should be conducted, and 
pointed out that the principal investigator of the interrupted studies was suspected of 
misconduct (ALESP 2018). In July, Professor Chierice entered a judicial action against PDT 
Pharma requiring the interruption of its Fosfo production, arguing that the drug was being 
inadequately produced without Professor Claro Neto’s supervision. The following year, 
however, Professor Chierice died unexpectedly due to an infarction. 
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Overall, the last interdiction of Fosfo did not prevent people from seeking access to it by 
diverse means. Fosfo assemblages proliferated through unregulated paths of scientific 
innovation in response to the prohibitive actions of established biomedicine. In a systematic 
search carried out on Facebook in September 2017, I found over one hundred regional, 
national and other self-defined groups of Fosfo supporters whose sizes ranged from thirty-
five to 47,000 members. Criticism against the use of immunosuppressive palliative therapies 
and the mainstream media was expressed in a confrontational fashion. Different recipes for 
producing Fosfo at home circulated among subscribers of blogs in favor of Fosfo and other 
immunostimulant therapies. Moreover, explanations about how to encapsulate Fosfo at home 
and other tutorials were made available on YouTube. In 2017, 2,889 lawsuits were brought to 
São Paulo state courts. These, and further practices described throughout this article, reveal 
and reinforce a detachment of medical science from established biomedicine. This duplication 
of biomedicine co-produces a shadow economy within which Fosfo users connect to each 
other and continuously deal with regulatory authorities, without necessarily being mediated by 
these authorities. How can this dynamic be understood? What happens to a person who gets 
in touch with Fosfo and becomes enmeshed in the controversy surrounding it? 
Apparently, focusing on the Fosfo case as a transfiguration process of established biomedicine 
in Brazil highlights aspects of how biomedicine resiliently regenerates itself through 
experiences of dissidence and, in particular, how this self-regeneration takes place through 
bionetworking activities. Nevertheless, is it possible to relate transfiguration to Fosfo? If so, 
how? What is transfiguration after all? In what follows, I explore these questions by 
experimentally using transfiguration as an analytical tool to understand Fosfo as a scientific 
controversy. 
Transfiguration: Bringing heaven to earth, or from a biblical 
narrative to a mundane experience 
The quintessential example of transfiguration is the biblical episode of the illumination of 
Jesus, when his appearance radically changes into a luminous form on a mountaintop as 
witnessed by three of his disciples (Matthew 17, 1–8). In his interpretation of Raphael’s 
painting of this episode, Friedrich Nietzsche (1872, as discussed in Strong 2010, 52) considers 
not only Jesus to be transfigured but also the ‘earth’ (i.e., the world around him). In so doing, 
Nietzsche not only expands transfiguration from the one who experiences it as an 
individuation process to the people around the transfigured person, but also contributes to 
dechristianizing transfiguration as a confessional phenomenon, while maintaining its religious 
character (Strong 2010). After bringing to life the notion of transfiguration as an existential 
experience, Nietzsche then compares it with the potential effects of how people deal with the 
work of art – an analytical tactic that, according to Venn (2000, 163), became ‘central to 
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modern aesthetics’. In The Birth of Tragedy, Nietzsche ([1872] 1993) addresses tragedy as a 
spectacle capable of provoking transfiguration by those who witness it, the spectators. 
According to Tracy Strong (2010, 54), for Nietzsche, ‘the experience of tragedy is paradigmatic 
of the experience of transfiguration’. Correspondingly, Nietzsche stimulates three conceptual 
displacements at the biblical narrative of transfiguration. First, Nietzsche anticipates the 
foundational character of modern understanding of transfiguration as a relational process, 
given that it may be understood as a radical mutual transformation that takes place between 
an individual and other individuals who compound one’s surroundings (see also Howie 2013, 
161). Second, he democratizes transfiguration as a phenomenon that occurs not only among 
holy entities but also among ordinary human people. Third, Nietzsche democratizes 
transfiguration as a phenomenon that can occur in ordinary situations too (Strong 2010, 57–
58). Contemporary examples provided by Oxford Dictionary Online (n.d.) illustrates that, such 
as: ‘if you thought Celtic music was fiddles, jigs and reels, this extraordinary album will be a 
platform for your transfiguration’. In this sense, transfiguration might refer to the effect of a 
transformation which takes place in daily life by an ordinary human person, and to a change 
not only of form but also of ways of feeling and perceiving which brings one to participate in 
a world re-ordering related to a dislocation of perspective. 
Might Fosfo act as a platform or catalyst for one’s transfiguration? Is that not what occurred 
when Carlos’s family and Fosfo came across each other? Not only did Carlos claim that his 
mother was cured by Fosfo, but also that other members of his family experienced radical life 
changes. They stopped waiting for an expected death after being told about an unexpected but 
wished-for possibility of cure. Moreover, they both adopted this possibility and propagated it, 
just as other Fosfo users did. Carlos’s family members and other Fosfo stakeholders began, as 
ordinary people, to feel, perceive, believe, and live differently, while they repositioned the 
status of conventional therapies and their associated regulatory institutions, and transgressed 
their norms. Hence, transfiguration as a process does not occur and spread without further 
concerns. There seem to be at least two complementary basic conditions for transfiguration 
to take place, if one understands it as the product of an encounter. 
Transfigurative numinous as storytelling materials 
In all examples of transfiguration that I have found in related literature, there is always 
something, normally a force, which meets the person who becomes transfigured. It is often 
described as light form. For example, in the German Wiktionary (n.d.), ‘Transfiguration’ is 
described as the ‘process by which Jesus’s mind was filled with higher, godly thoughts’. In the 
examples of transfiguration mentioned above, this holy/healing force appears as the unknown 
music album, and as a compound. Both come from somewhere else. The radiation of the 
album’s songs, and Fosfo’s biochemicals, draining into the listeners’ mundane body, actualizes 
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their body and their reality. What kind of force is that without which no transfiguration takes 
place? 
Apparently, this force becomes itself relationally materialized through the very encounter that 
produces transfiguration. In the description of Jesus’s transfiguration in Wiktionary (n.d.), for 
instance, ‘godly thoughts’ are designated as substances that can ‘fill’ the ‘mind’ of Jesus. Here, 
both ‘mind’ and ‘thoughts’ assume a material character, such as the image of a cup of water. 
This image, however, should not be taken as corresponding to Descartes’ dichotomy between 
body and mind, whereby the former is seen as a vehicle rationally driven by the latter. The 
point is that there is no Jesus’s mind without its divine thoughts. It is the connective, 
communicative, and productive aspects of the meeting between transfigurative force and 
transfiguring person that I want to emphasize. Likewise, music is often evoked as capable of 
triggering transfiguration (Gilroy 1993; Mbembe 2005; Strong 2010). As Achille Mbembe 
(2005, 72) puts it: 
The aesthetic signification of a musical work is revealed through that which links the 
work to a world of sensations. Musical beauty therefore has meaning in – and through 
– its effects, through the feelings and passions that the musical work produces in the 
subject who is listening to it, is present at its performance or is dancing in 
accompaniment of it. 
By the same token, as a biotechnological work and a biosocially constituted hope to cure 
cancer, Fosfo has meaning through its effects on cancer patients; there is no Fosfo user 
without Fosfo as ‘the cancer pill’ and vice versa.  
Thus, the transfigurative force tells a story, a narrative. It transmits a new frequency or melody 
and provokes new sensations. Mostly, it is an unknown outsider and, therefore, what it tells 
does not necessarily belong to the here and now – it is mostly unpredictable. It comprises 
signs that, in the context of transfiguration, may be seen as ‘numinous’ (Otto [1917] 1936) 
and, thus, have a mythological property. As signs, these transfigurative substances are not only 
objects of interpretation but are themselves already interpretations (Foucault [1967] 1998, 277) 
that intervene on already circulating, established ones. In this sense, these signs are semiotic 
materials and material semiotics at once (Miller 2010). Hence, what the transfigurative 
numinous substance as storyteller material has to offer is what Venn (2000, 177), calls a 
‘renarrativization’ of one’s life as one knew it until that moment. Is that not what Fosfo as a 
medical future promises? 
Fosfo reminds those cancer cells that persist to live that they forgot to die, and chronic patients 
that they are not chronic at all. In this light, the affectivity of Fosfo as unauthorized biopolitical 
artefact in building life assemblages which seek to promote a transfiguration of cancer 
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treatment and the established medico-legal regime in Brazil becomes clearer. As a travelling 
medico-technological artefact, Fosfo disseminates a particular biopolitical agenda, which is 
simultaneously an object to be appropriated, a message, and an intervening practice (Lakoff 
2007; Foucault [1967] 1998). Hence, if understood as a numinous storytelling material that 
comes from the world of unauthorized therapies, the recovery process through Fosfo 
improves immunological awareness as the body’s capacity to know and properly deal with other 
constituents of oneself (Napier 2012). This is true at least according to many available Fosfo 
users’ narratives (Cura do Câncer n.d.). Maybe it could be seen as a storyteller’s gift, one that 
may or may not be properly accepted by those who encounter it, from Fosfo users’ cells to 
authorities at governmental, educational, and private institutions. Here, I come to the second 
condition of transfiguration: the creative receptivity of cancer patients as spectators, without 
whom there is also no tragedy. 
Active receptivity and transgression of legal norms 
To experience transfiguration, one must have a willingness, a longing, and the appropriate 
receptivity to allow the forces that might trigger it to act. At the corporeal level of the Fosfo 
controversy, transfiguration might take place as the immune systems of Fosfo users read the 
message printed on cancer cells by the drug and re-learn their role as a fundamental actor 
within the healing process. The wish to become part of and/or immersed in the story, which 
materials of transfigurative numinous tell, belongs to this inclination. One might say that one’s 
predisposition to experience transfiguration is mainly based on the Nietzschean assumption 
that:  
the self is not found at home […] but achieved. The picture is not of turning around 
but of a path, a kind of growth […]. Successful tragedy for Nietzsche constitutes the 
sealing of a change not so much in what one is but in the naturalness by which one is 
able to deal in one’s life and history with the historically evolving conditions that affect 
a culture. (Strong 2010, 56) 
Similarly, Foucault ([1967] 1998) conceives the person who can reproduce or actualize 
themselves as a work of art as potentially characterizing a mode of emancipation. As Venn 
(2000, 155) explains: ‘Foucault summarizes his approach in the concept of a “critical ontology” 
that inscribes a being for whom autonomy and freedom are the conditions for the “complex 
and difficult elaboration” through which it transforms itself into a “work of art”’. Following 
that, both Nietzsche and Foucault divide the spectators of the tragedy, or the beings who 
recreate themselves aesthetically, between those who gather these conditions (i.e., those who 
cease to ‘rationalize’ and instead have a Dionysian attitude towards tragedy as ‘true aesthetic 
listener’) and those who, in contrast, belong to the ‘community of Socratic-critic persons’ 
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(Strong 2015, 55). That is why, for Nietzsche, the ‘true listener’ is ‘capable of understanding 
myth [the transfigurative numinous] as a concentrated image of the world that, as a 
condensation of phenomena, cannot dispense with miracles’ (Nietzsche 1872, cited in Strong 
2010, 55). Therefore, the creative receptivity of the spectator co-produces them as true. 
Accordingly, the subject Foucault envisions, 
who has returned with an ‘attitude’, is not to be confused with the self-present, imperial 
subject of logocentric Reason, for it is now an anxious figure haunted by the idea of its 
finitude, compelled by the task of ‘inventing itself’ but within ‘the limits that are 
imposed’ on it […]. [The one who transfigures is rather] a Dionysian being whose will 
to power seeks not dominion over others but a form of plenitude – epiphanic perhaps 
– through the ecstatic and sublime experience of the artistic, inventive transfiguration 
of oneself. (Venn 2000, 155) 
Both Dionysian and Apollonian spectators are incarnated by different people who, for 
instance, accompany, discuss, and dispute the interpretation of the results of clinical tests with 
Fosfo on the internet (VK n.d.; AMUCC 2016). However, what is important to emphasize 
here is that, if one assumes the Foucauldian condition that transfiguration does not take place 
within the limits imposed on it by modernity, then a self-reinvention process does not 
necessarily characterize or provoke transfiguration. One must go beyond it. 
In my opinion, patients with autoimmunity that seek to re-create their lives through 
unconventional and unauthorized immunostimulating therapies, while wishing to abandon 
immunosuppressive therapies, are on the same trail. From the perspective of Fosfo users, a 
substantial part of the limitations that cancer patients encounter comprises legal norms that 
act as counterforces that prevent transfiguration from taking place and keep cancer patients 
under therapeutic oppression. Another substantial part of these limitations relates to the non-
communicable disciplinary inconceivability linked to the dogmas of immunosuppression as a 
hegemonic therapeutic model, as taught in Brazilian medical schools. Given that, what do 
immunostimulant therapies have to offer to people with autoimmunity? Which story does 
Fosfo have to tell? 
Fosfo also speaks through its users and stakeholders. In the context of pharmaceutical 
prohibition, to carefully listen to and participate in a forbidden narrative is an act of 
transgression linked to the pursuit of freedom that qualifies one’s self-reinvention and opens 
up the possibility of transfiguration. Thus, on the one hand, accepting miracles or utopias 
(which are not motivated by biomedically accepted evidence as reported by transfigured Fosfo 
users and stakeholders) as a condition for transfiguration implies the transgression of 
boundaries that were established to prevent one’s self-reinvention. On the other hand, since 
transfiguration only takes place through transgression of established boundaries, legal norms 
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are necessary. In this way, one’s self-reinvention as transfiguration journey inevitably becomes 
an expression of, and therefore a means to produce, deviance as a potential groundbreaking 
innovation. 
Ethical imagination and medical futures 
Established biomedicine locks cancer patients, like other people with symptoms of 
autoimmunity, into chronicity. The term has an ambiguous meaning; sometimes being a 
chronic patient means being forever ill, whereas other times it refers to the unpredictability of 
their illness. Biomedical chronicity appears, in this sense, as a particular temporal frame within 
which chronic patients not only wait for a cure that established biomedicine promises to 
provide in the future, but also within which they adaptively co-generate the appropriate 
consciousness and affects which help them to live as chronic patients. Hence, while the 
hegemonic therapeutic model of immunosuppression currently offered by biomedicine (as 
well as the newest biotechnological innovations based on the same principle) stand for a 
politics of fulfilment, Fosfo and other marginalized immunostimulant therapies figure as 
utopias. For Fosfo users and stakeholders, undergoing chemotherapy and radiotherapy is 
useless and somewhat disturbing, if one knows of another therapeutic possibility that may 
even cure. The idea of this possibility alone, supported by evidence created as much by 
scientists as by patients through their bionetworking activities, is very powerful, even when 
contested by medico-legal authorities. This is because it portrays conventional treatments not 
only as medically outdated and inappropriate but also as morally unsustainable. 
In this scenario, the true spectator’s longing to transfigure concomitantly seems to be 
associated with an impulse to embrace and participate in the making of another possible future 
that produces a rupture with the known present as an ‘effect of a curative renarrativization of 
what has come to pass’ (Venn 2000, 50). In consonance with the shared openness to accept 
miracles on the stage, the predisposition to embark upon a new story, or the attitude of 
searching for plenitude, Paul Gilroy (1993) writes about how conceiving utopias of 
emancipation emerge as parts of the ‘politics of transfiguration’ – a concept that he borrows 
from Seyla Benhabib (1985), together with that of ‘fulfilment’. By ‘transfiguration’, Benhabib 
(1985, 84–85) explains: 
I mean that the future envisaged by a theory [or, a story] entails a radical rupture with 
the present, and that in such a rupture a new and imaginative constellation of the values 
and meanings of the present takes place. The concept of fulfilment, by contrast, refers 
to the fact that the society of the future executes and carries out the unfinished tasks 
of the present, without necessarily forging new, imaginative constellations out of this 
cultural heritage. 
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Both concepts of fulfilment (associated with norm) and transfiguration (utopia) address 
complementary and distinct modalities of emancipation which are analogous to the 
Apollonian-Dionysian tension, with which Nietzsche and Foucault worked. Gilroy (1993) 
adopts them to address the ambiguous conditions and belongings of slave descendants within 
the context of the African diaspora in Europe, while he refers to their co-existence within the 
same person as implying a ‘double consciousness’. This duplicity may be viewed as similar to 
the status of cancer patients who are aware of navigating through and between the formal 
Brazilian private and public healthcare system and its shadow by engaging in informal 
bionetworking activities to promote unauthorized biotechnological innovations. 
Transfigured person, transfigured world 
When the conditions for transfiguration to occur are met (i.e., there is an exogenous 
transfigurative element that meets a proper receiver who wishes to experience a new story by 
which one inevitably participates in a transgression of norms), a proliferation of bodies and 
consciousnesses begins. This can be understood as a numinous experience (i.e., the way people 
experience their own existence and modes of feeling themselves as being alive through their 
encounters with the unknown as other). As Nietzsche (1872, cited in Strong 2010, 53) puts it, 
transfiguration takes place at a first moment as ‘one’s own [transformation] experience, to 
which, however, one is a witness’. When one experiences a tragedy properly, one undergoes an 
‘internal bifurcation’ that provokes a state of ecstatic ‘doubleness’: ‘one is literally besides 
oneself’ (ibid., 54). As the two features of the now ‘self-uninstalled’ (Vilar 2018b) spectator – 
the Dionysian and Apollonian – are complementary facets which get along with each other 
dialectically, the process of transfiguration, for Nietzsche (1872, cited in Strong 2010, 55), goes 
on: 
In this enchanted state, the dionysian reveler sees himself as a satyr, and as a satyr, in 
turn he sees the god, which means that in his transformation he beholds another vision 
outside himself, as the apollonian perfection to his own state. With this new vision, the 
drama is complete. 
By evolving within the person, who has accepted it in a proper way, the storyteller material as 
the transfiguration trigger unwinds this up to a further existential potentiality, so much so that 
the transfigured person becomes something else or a new entity assigned with differentiated 
power, and it remains the same. 
From a Cartesian perspective, this appears to be a flagrant contradiction. However, if one 
considers persons as being made of further persons, or actors that are also networks, then it 
appears an issue about which aspect of oneself is in charge or becomes dominant in a given 
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entanglement. Then transposed to the context of disputes between immunosuppressive and 
immunostimulant therapies, this transfiguration is the unrolling of biomedicine from inside 
out, through its contact with immunostimulants. So much so that biomedicine, at least 
partially, re-organizes itself by overlaying its current established model of immunosuppression 
with that part of itself which promotes its opposite principle of immunostimulation as a 
potential legitimate medical future to tackle autoimmunity. 
Likewise, disputing a legitimate ethical position within contemporary biopolitical regimes of 
self and self-monitoring (Rose and Novas 2005, 441–442), immunostimulating therapies 
present themselves as new medical narratives capable of providing technologies and 
knowledge that enable the patients to recognize, validate, and recommit specific parts that co-
constitute themselves (such as their immune systems), instead of suppressing them as 
conventional treatments do. Through contact with Fosfo, immunostimulant-users 
demonstrate that the self-regeneration of a person – or cure as transfiguration – is reached 
through its adequate interaction with and assimilation of an other (i.e., of non-selves within its 
immediate environment). However, a whole set of others belong to one’s environment.  
At least to some extent, one cannot change one’s own reality, or self-reinvent through 
unauthorized treatments, without affecting the reality of others. Moreover, others may also 
act as sources or mediators of transfigurative storytelling materials. As Strong (2010, 54) 
resumes: ‘The dionysian excitement can communicate this artistic gift to a multitude, that of 
seeing themselves surrounded by such a host of spirits, knowing that one is inwardly one with 
them’. When patients with autoimmunity transgress institutional borders by embracing 
immunostimulant therapies so as to become who they are as healthy people, they are crossing 
the same borders which co-organize the world of other people who are witnessing their 
transgression. The testimony of a forum participant, during a discussion about the results of 
Fosfo tests on the internet, illustrates this point: 
I just met a girl who had breast and liver cancer. She has exams before and after [Fosfo]. 
She used Fosfo for one year and a half. Healed!!! Yes… She did not have chemo and 
radiotherapy. And it’s not just her… It’s a lot of people. […] I met a doctor who […] 
did not even want to listen [about Fosfo]. Suddenly, my uncle, one of his best friends, 
had cancer. Do you know that he did research on the topic and changed his mind about 
Fosfo? (AMUCC 2016) 
Just like fear, hope can be contagious too. Hence, as other people in the Witthoeft family’s 
village wished to know more about Fosfo and how to obtain it, one’s own transfiguration 
directly affects other surrounding persons, while one might be transfigured through other 
persons’ transfigurations (Howie 2013, 161). 
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Conclusion 
In this article, I sought to anthropologically understand the emergence of Fosfo worlds, in the 
context of institutional crisis and increasing judicialization of life in Brazil, in terms of 
transfiguration. To achieve this, I followed Fosfo as a travelling biotechnological and political 
artefact that circulates through and between the internet, medical offices, laboratories, 
ambulatories, universities, courts, advocacy offices, associations, and family homes. In so 
doing, I observed that, while Fosfo spreads an immuno-political agenda at multiple levels and 
co-generates life assemblages, those who allow themselves to be affected by it and become 
Fosfo users and/or stakeholders engage in practices to promote the treatment as a scientific 
innovation for health as acts that imply a deviant co-regulation of immunity. Paradoxically, the 
coming-into-being of Fosfo worlds through transfigurative encounters between Fosfo and 
potential life assemblages’ members occurs only as entangled with innovative developments 
in and their regulation by established biomedicine. In this sense, Fosfo worlds responsively 
unfold as aligned processes of transformation, or infrastructuring, that take place by re-coding 
and co-opting already existing infrastructures (e.g., juridical, communicational, and scientific). 
Correspondingly, by focusing on how Fosfo assemblages’ members evaluate and act towards 
competing therapeutic models to treat cancer, it becomes possible to apprehend aspects of an 
immunological sociality that informs the conceptualization of persons and moralities and 
which are mostly not taken into account by established biomedicine. Thus, to apprehend the 
transfiguration of juridical and physical persons involved in Fosfo’s controversy as effects of 
Fosfo, and through the engagement of Fosfo users, might help to understand how the 
materials, knowledge, legal resources, and health and moral values that they circulate and 
assemble – including substances, laboratory instruments, ideas of scientific innovation, online 
and offline exchanges, cure and necessary transgression – are repositioned through their 
bionetworking activities as to regenerate biomedicine. Mainly, as a science that seeks to heal. 
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